EUR/USD likely to find a peak near 1.25: UBS
David Linetsky, Senior Vice President of Life Sciences at Phreesia, Inc. (NYSE:PHR), has recently sold shares of the company’s common stock, according to a regulatory filing. The transactions, which took place on March 18 and 19, involved the sale of 127 shares, totaling approximately $3,504. The healthcare technology company, currently valued at $1.63 billion, has seen impressive momentum with a ~14% gain over the past week.
The sales were executed at weighted average prices ranging from $26.9507 to $28.3112 per share. These transactions were part of non-discretionary sales under Phreesia’s mandatory sell-to-cover policy, designed to cover tax withholding obligations related to the settlement of restricted stock units. Following these transactions, Linetsky indirectly holds 8,724 shares through his spouse, while directly holding 218,135 shares of Phreesia stock. According to InvestingPro analysis, analysts maintain a strong buy consensus with price targets ranging from $29 to $36, suggesting potential upside from current levels.
In other recent news, Phreesia Inc . has seen a series of analyst updates following its recent financial performance. Jefferies raised its price target for Phreesia to $32, maintaining a Buy rating, based on the company’s fourth-quarter earnings and management’s commentary, which highlighted Phreesia’s operational leverage and strategic focus on Network Solutions. KeyBanc Capital Markets also reiterated an Overweight rating with a $30 target, emphasizing the company’s margin improvement and anticipated revenue growth driven by Network Solutions. Raymond (NSE:RYMD) James maintained an Outperform rating with a $30 target, noting Phreesia’s shift towards a free cash flow-oriented narrative, which is expected to enhance earnings conversion into cash flow.
DA Davidson reiterated a Buy rating with a $36 target, citing Phreesia’s solid fiscal year 2025 results and its undervaluation compared to peers. The firm emphasized the company’s consistent performance and strategic value creation in the healthcare services sector. Canaccord Genuity increased its price target to $35, maintaining a Buy rating, and highlighted Phreesia’s positive adjusted EBITDA achievement, expanding margins, and growing healthcare service client base. The firm’s analysis pointed to Phreesia’s strong operating leverage and cash flow improvements, with expectations for continued financial growth. These developments reflect a broader confidence among analysts in Phreesia’s business model and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.